Confirmation of secondary listing on the JSE

Released : 14 Nov 2024

RNS Number : 1309M
Assura PLC
14 November 2024
 

14 November 2024

 

Assura plc

Confirmation of secondary listing on the Johannesburg Stock Exchange

Assura plc ("Assura" or the "Company"), the UK's leading diversified healthcare REIT, is pleased to confirm that the Johannesburg Stock Exchange ("JSE") has granted approval to Assura for a secondary listing on the Main Board of the JSE. The commencement of trading is expected to take effect on Thursday, 21 November 2024.

The Company has released a pre-listing announcement ("PLA") in relation to a secondary inward listing on the Main Board of the JSE by way of an introduction.

Assura continues to see opportunities in providing critical healthcare infrastructure and believes that this secondary listing will provide a new potential pool of capital to fund the Company's continued growth.

In particular, the listing will enable Assura to:

·    give South African investors a local platform to more easily invest in and trade Assura shares;

·    broaden the Company's shareholder base with new South African investors;

·    increase liquidity for shareholders; and

·    diversify the Company's shareholder base and position it for future growth.

The Company will not place or issue any new Assura shares in connection with its application for a secondary listing on the JSE and will remain listed on the Equity Shares (Commercial Companies) category (ESCC) of the Official List in London.

HSBC is acting as Listing Co-ordinator and Corporate Broker and Nedbank Corporate and Investment Banking, a division of Nedbank Limited, as Corporate Advisor and JSE Sponsor.

Jonathan Murphy, CEO, said:

"We are delighted that our secondary listing on the Johannesburg Stock Exchange, which we believe will contribute to liquidity in our shares, has been approved.

As the UK's leading diversified healthcare REIT, Assura offers an attractive proposition to South African investors. We look forward to welcoming them onto our share register. Our high quality assets offer long-term secured and growing income, underpinned by the long-term structural demand for healthcare services."

- Ends -

For more information, please contact:

 

Assura plc

 

Tel: 0161 515 2043

David Purcell, Investor Relations Director

Email: [email protected]

 

FGS Global

Gordon Simpson

Grace Whelan

 

 


Tel:
 0207 251 3801

Email: [email protected]

HSBC Bank Plc

Chloe Ponsonby

Jonathan Surr

Louis Davies

Tel: 020 7991 8888


Notes to Editors

Assura plc is the UK's leading diversified healthcare REIT. Assura enables better health outcomes through its portfolio of more than 600 healthcare buildings, from which over six million patients are served.

UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA* indices. As at 30 September 2024, Assura's portfolio was valued at £3.2 billion and has a strong track record of growing financial returns and dividends for shareholders.

At Assura, we BUILD for health, having developed over 100 new healthcare buildings in our history, and at the heart of our strategy sits The Bigger Picture; Healthy Environment (E), Healthy Communities (S), Healthy Business (G).

Further information is available at www.assuraplc.com

*EPRA is a registered trademark of the European Public Real Estate Association

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFEVLDLVLIS